Kimura H, Yamaguchi Y
Division of Thoracic Diseases, Chiba Cancer Center, Japan.
Lung Cancer. 1996 Jun;14(2-3):301-14. doi: 10.1016/0169-5002(96)00555-7.
Out of 642 primary lung cancer patients who underwent surgery between 1986 and 1992, 82 cases who underwent curative resection were enrolled for a randomized prospective controlled study of postsurgical adjuvant immunotherapy using Interleukin 2 (IL-2) and lymphokine activated killer (LAK) cells. From 1986 to 1989 (the initial period), Stage IIIA patients were divided into three groups: group A (chemo-immunotherapy) received IL-2, LAK cell adoptive immunotherapy after two courses of anticancer (CDDP, VDS, MMC) chemotherapy, group B (control) received no adjuvant therapy, and group C (chemotherapy) received the same anticancer chemotherapy as group A. In the latter (1990-1992) period, group C was discontinued because of poor results and Stage II and IIIA cases were randomly assigned to group A or B. The 5- and 7-year survival rates of group A (33 cases) and B (36 cases) were 58.2% and 31.5%, respectively in Stage II and IIIA cases. The prognosis of group A was significantly better than that of group B (P = 0.0038 by the Cox-Mantel (C-M) test and 0.0033 by the generalized Wilcoxon (G-W) test). The 5- and 8-year survival rates of each group for Stage IIIA cases were 53.4% (group A, 25 cases), 33.4% (group B, 26 cases), and 30.8%, 15.3% (group C, 13 cases). The prognosis of group A was significantly better than that of group B (P = 0.045 by the C-M and 0.036 by the G-W test). The difference between group A and B was also significant in N0, N1 (P < 0.01), in T1, T2 (P < 0.01), and T3 (P < 0.05) cases. These results indicate that adjuvant immunotherapy using IL-2 and LAK cells in combination with chemotherapy is significantly effective in improving the postsurgical prognosis of lung cancer patients.
在1986年至1992年间接受手术的642例原发性肺癌患者中，82例行根治性切除术的患者被纳入一项关于使用白细胞介素2（IL-2）和淋巴因子激活的杀伤细胞（LAK细胞）进行术后辅助免疫治疗的随机前瞻性对照研究。从1986年至1989年（初期），ⅢA期患者被分为三组：A组（化疗免疫治疗）在进行两个疗程的抗癌（顺铂、长春地辛、丝裂霉素）化疗后接受IL-2、LAK细胞过继免疫治疗；B组（对照组）不接受辅助治疗；C组（化疗组）接受与A组相同的抗癌化疗。在后期（1990年至1992年），由于效果不佳C组被停用，Ⅱ期和ⅢA期病例被随机分配至A组或B组。在Ⅱ期和ⅢA期病例中，A组（33例）和B组（36例）的5年和7年生存率分别为58.2%和31.5%。A组的预后明显优于B组（Cox-Mantel（C-M）检验P = 0.0038，广义Wilcoxon（G-W）检验P = 0.0033）。ⅢA期病例中每组的5年和8年生存率分别为53.4%（A组，25例）、33.4%（B组，26例）以及30.8%、15.3%（C组，13例）。A组的预后明显优于B组（C-M检验P = 0.045，G-W检验P = 0.036）。在N0、N1（P < 0.01）、T1、T2（P < 0.01）以及T3（P < 0.05）病例中，A组和B组之间的差异也具有显著性。这些结果表明，IL-2和LAK细胞联合化疗的辅助免疫治疗在改善肺癌患者术后预后方面具有显著效果。
